Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2009

View Archived Issues

Novel anticancer compounds in early development at Pharminox

Dainippon Sumitomo Pharma discovers new renin inhibitors for the treatment of hypertension

HDAC inhibitors claimed by CrystaX Pharmaceuticals for cancer treatment

Debiopharm and Mercury sign exclusive license agreement for Debio-0930

Novartis initiates shipments of seasonal flu vaccine Fluvirin to U. S. for 2009-2010 season

FDA extends PDUFA date for Pennsaid NDA to November 2009

FDA accepts for review Kamada's BLA for IV-AAT for alpha-1 antitrypsin deficiency

FDA approves Firmagon name for Ferring's prostate cancer treatment degarelix

Progenics and Wyeth submit applications to FDA and EMEA for Relistor prefilled syringes

Phase Ib data show antitumor activity of low-dose NGR-hTNF in advanced solid tumors

Carisbamate reduces alcohol preference and intake in alcohol-preferring rats

No difference in viral dynamics in ABC/3TC and TDF/FTC in ART-naive HIV-1 subjects

Mirabegron does not affect PK, PD and safety profiles of metformin in healthy adults

EMEA withdraws marketing authorization for Posaconazole SP

Cilostazol confers neuroprotection in rat model of cerebral hypoperfusion

TRPV1 vanilloid receptor antagonists disclosed by Glenmark Pharmaceuticals

Vereniging VU-Windesheim presents H4 receptor ligands for the treatment of inflammatory disorders

PPAR agonists synthesized for the treatment or prevention of diabetes at sanofi-aventis

Labopharm files NDS with Health Canada for formulation of antidepressant trazodone

NicOx to reacquire development and commercialization rights to PF-03187207 from Pfizer

Bellicum initiates dosing in phase I/II clinical trial of BP-GMAX-CD1 in prostate cancer

EMEA grants orphan drug designation to Aradigm's inhaled liposomal ciprofloxacin in CF

European Commission grants marketing authorization to Genzyme's Mozobil

ProStrakan submits Abstral NDA to FDA for breakthrough cancer pain

Galapagos reports results from phase I trial of GLPG-0259 in rheumatoid arthritis

FDA extends PDUFA date from August to November 2009 for NeurogesX's Qutenza NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...